Go Pro
→ How Long Does $2.5M Last in Retirement? (From SmartAsset) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$0.75
-18.0%		$0.55
$0.00
▼
$3.73
$9.74M0.838,262 shs1,146 shs
Gelteq Limited stock logo
GELS
Gelteq
$0.89
+27.6%		$0.59
$0.39
▼
$2.02
$7.50M-0.413.60 million shs69.51 million shs
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
$4.43
+1.4%		$3.44
$1.92
▼
$34.63
$10.02M1.7291,906 shs21,390 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.75
-25.0%		$1.05
$0.31
▼
$1.50
$1.95M1.13,195 shs523 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
-18.03%-18.92%+102.70%+25.00%-75.77%
Gelteq Limited stock logo
GELS
Gelteq
+27.60%+56.67%+67.39%+79.72%-20.25%
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
+1.37%+2.78%+38.87%+26.21%-73.25%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-25.00%+4.70%-33.04%-25.00%+37.51%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$0.75
-18.0%		$0.55
$0.00
▼
$3.73
$9.74M0.838,262 shs1,146 shs
Gelteq Limited stock logo
GELS
Gelteq
$0.89
+27.6%		$0.59
$0.39
▼
$2.02
$7.50M-0.413.60 million shs69.51 million shs
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
$4.43
+1.4%		$3.44
$1.92
▼
$34.63
$10.02M1.7291,906 shs21,390 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.75
-25.0%		$1.05
$0.31
▼
$1.50
$1.95M1.13,195 shs523 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
-18.03%-18.92%+102.70%+25.00%-75.77%
Gelteq Limited stock logo
GELS
Gelteq
+27.60%+56.67%+67.39%+79.72%-20.25%
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
+1.37%+2.78%+38.87%+26.21%-73.25%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-25.00%+4.70%-33.04%-25.00%+37.51%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
0.00
N/AN/AN/A
Gelteq Limited stock logo
GELS
Gelteq
1.00
SellN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
1.00
SellN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VCNX, PBM, EGRX, and GELS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/26/2026
Gelteq Limited stock logo
GELS
Gelteq
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/11/2026
Gelteq Limited stock logo
GELS
Gelteq
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$257.55M0.04$1.88 per share0.40N/A∞
Gelteq Limited stock logo
GELS
Gelteq
$110K86.97N/AN/A$1.08 per share0.83
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/A$7.39 per shareN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K5.03N/AN/A($2.59) per share-0.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$35.64M$1.180.64N/AN/AN/AN/AN/A11/9/2026 (Estimated)
Gelteq Limited stock logo
GELS
Gelteq
-$4.30MN/AN/AN/AN/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
-$6.94M$25.340.17N/AN/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/AN/A-383.58%11/16/2026 (Estimated)

Latest VCNX, PBM, EGRX, and GELS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/30/2026Q2 2026
Gelteq Limited stock logo
GELS
Gelteq
N/A-$0.12N/A-$0.12N/AN/A
6/22/2026Q4 2026
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A-$0.41N/A-$0.4050N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/AN/AN/A
Gelteq Limited stock logo
GELS
Gelteq
N/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/A
Gelteq Limited stock logo
GELS
Gelteq
N/A
0.09
N/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A
14.62
14.62
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
85.36%
Gelteq Limited stock logo
GELS
Gelteq
N/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
77.44%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%

Insider Ownership

CompanyInsider Ownership
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
28.90%
Gelteq Limited stock logo
GELS
Gelteq
N/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
3.60%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
10012.99 million9.23 millionNo Data
Gelteq Limited stock logo
GELS
Gelteq
N/A10.71 millionN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A2.29 million2.21 millionN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
402.60 million1.26 millionNo Data

Recent News About These Companies

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
Vaccinex announces $60M revenue sharing agreement with PDV
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/vaccinex-announces-60m-revenue-sharing-agreement-with-pdv/ar-AA1SUmDZ
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 23, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease-1035667359
Vaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s Treatment
December 23, 2025  |  quiverquant.comQ
Vaccinex presents promising cancer treatment data at ASCO
May 29, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/vaccinex-presents-promising-cancer-treatment-data-at-asco-93CH-4104876
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025
May 29, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/vaccinex-inc-present-new-data-pepinemabs-role-enhancing-immune-responses-head-and-neck
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
May 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/27/3088645/34858/en/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting.html
AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65384714-abtherx-inc-abtherx-single-cell-technology-and-vaccinex-announce-collaboration-to-tackle-challenging-antibody-drug-targets-200.htm
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/abtherx-single-cell-technology-vaccinex-100000437.html
Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy
April 22, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-report-new-clinical-data-on-pepinemab-in-enhancing-immunotherapy-1034603197
Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025
April 21, 2025  |  quiverquant.comQ
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
April 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/21/3064665/34858/en/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemab-s-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr.html
Vaccinex director resigns, no disagreement cited
March 21, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/vaccinex-director-resigns-no-disagreement-cited-93CH-3937856
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows
March 10, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vaccinex-plans-nasdaq-exit-alzheimer-211545558.html
Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 8, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64767350-vaccinex-inc-vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market-399.htm
Vaccinex to delist common stock from Nasdaq
March 7, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-delist-common-stock-from-nasdaq-1034455385
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/07/3039274/34858/en/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eagle Pharmaceuticals stock logo

Eagle Pharmaceuticals NASDAQ:EGRX

$0.75 -0.17 (-18.03%)
As of 09/3/2026 01:39 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Gelteq stock logo

Gelteq NASDAQ:GELS

$0.89 +0.19 (+27.60%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$0.81 -0.08 (-9.20%)
As of 08:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Psyence Biomedical stock logo

Psyence Biomedical NASDAQ:PBM

$4.43 +0.06 (+1.37%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$4.39 -0.04 (-0.90%)
As of 07:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$0.75 -0.25 (-25.00%)
As of 09/3/2026 03:37 PM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas